• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.

作者信息

Saif Muhammad Wasif

机构信息

Tufts University School of Medicine. Boston, MA, USA.

出版信息

JOP. 2013 Nov 10;14(6):686-8. doi: 10.6092/1590-8577/2028.

DOI:10.6092/1590-8577/2028
PMID:24216565
Abstract
摘要

相似文献

1
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.美国食品药品监督管理局批准将紫杉醇蛋白结合微粒（Abraxane®）与吉西他滨联合用于转移性胰腺癌患者的一线治疗。
JOP. 2013 Nov 10;14(6):686-8. doi: 10.6092/1590-8577/2028.
2
First line therapy for metastatic pancreatic cancer.转移性胰腺癌的一线治疗。
JOP. 2013 Jul 10;14(4):340-3. doi: 10.6092/1590-8577/1667.
3
Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.转移性胰腺癌中纳武单抗联合吉西他滨与单纯吉西他滨治疗的质量调整生存期：一项Q-TWiST分析
J Med Econ. 2014 May;17(5):338-46. doi: 10.3111/13696998.2014.903122. Epub 2014 Mar 21.
4
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.纳武利尤单抗联合伊匹木单抗治疗晚期不可切除肝细胞癌的多中心、开放标签、Ib 期研究
Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.
5
Treatment of metastatic pancreatic adenocarcinoma: a review.转移性胰腺导管腺癌的治疗：综述。
Oncology (Williston Park). 2014 Jan;28(1):70-4.
6
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.吉西他滨联合白蛋白紫杉醇在晚期胰腺癌患者中具有活性：一项 I/II 期试验。
J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.
7
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).吉西他滨联合 nab-紫杉醇直至进展或与 FOLFIRI 交替使用 3，作为转移性胰腺腺癌患者的一线治疗：法语国家消化肿瘤学联盟-PRODIGE 37 随机 2 期研究（FIRGEMAX）。
Eur J Cancer. 2020 Sep;136:25-34. doi: 10.1016/j.ejca.2020.05.018. Epub 2020 Jul 2.
8
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.美国食品药品监督管理局批准帕博利珠单抗联合化疗用于局部复发性不可切除或转移性三阴性乳腺癌
Oncology (Williston Park). 2020 Dec 7;34(12):547. doi: 10.46883/ONC.2020.3412.0547.
9
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.CD40 激动性单克隆抗体 APX005M（替戈利木单抗）联合化疗，联合或不联合纳武利尤单抗，用于治疗转移性胰腺导管腺癌：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2021 Jan;22(1):118-131. doi: 10.1016/S1470-2045(20)30532-5.
10
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.白蛋白结合型紫杉醇与吉西他滨联合应用对原发性及转移性胰腺癌病灶的肿瘤缩小作用：一项3期研究的探索性分析
Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742.

引用本文的文献

1
Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.靶向癌症相关成纤维细胞驱动的LIF/LIFR轴可提高吉西他滨和纳米白蛋白结合型紫杉醇在胰腺癌中的治疗效果。
NPJ Precis Oncol. 2025 Aug 22;9(1):296. doi: 10.1038/s41698-025-01046-w.
2
A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer.一项真实世界回顾性队列研究：铂耐药复发性卵巢癌的临床结局与特征
Transl Cancer Res. 2025 May 30;14(5):3161-3174. doi: 10.21037/tcr-2025-641. Epub 2025 May 27.
3
The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations-a narrative review.
纳米医学与人工智能在癌症医疗中的作用：个体应用与新兴整合——一项叙述性综述
Discov Oncol. 2025 May 8;16(1):697. doi: 10.1007/s12672-025-02469-4.
4
Controlled and Targeted Drug Delivery Using Smart Nanovectors.使用智能纳米载体的可控靶向药物递送
Int J Drug Discov Pharm. 2023 Mar;2(1):84-90. doi: 10.53941/ijddp.0201010. Epub 2023 Mar 20.
5
Biodegradable Zwitterionic Polymers as PEG Alternatives for Drug Delivery.可生物降解的两性离子聚合物作为聚乙二醇的替代物用于药物递送
J Polym Sci (2020). 2024 May 15;62(10):2231-2250. doi: 10.1002/pol.20230916. Epub 2024 Mar 5.
6
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.BET 抑制降低 HMGCS2 水平并增强吉西他滨对耐药胰腺肿瘤的敏感性。
Cancer Lett. 2024 Jun 28;592:216919. doi: 10.1016/j.canlet.2024.216919. Epub 2024 May 3.
7
Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma.基于连接性图谱鉴定侵袭性胰腺导管腺癌中靶向HDAC6的药理抑制剂
NPJ Precis Oncol. 2024 Mar 7;8(1):66. doi: 10.1038/s41698-024-00562-5.
8
Recent Advancements and Strategies for Overcoming the Blood-Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma.利用基于白蛋白的药物递送系统克服血脑屏障治疗脑癌的最新进展与策略，重点关注胶质母细胞瘤
Polymers (Basel). 2023 Oct 2;15(19):3969. doi: 10.3390/polym15193969.
9
Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.临床试验中的抗癌纳米疗法：纳米医学临床转化背后的工作。
Int J Mol Sci. 2022 Nov 2;23(21):13368. doi: 10.3390/ijms232113368.
10
Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis.化疗诱导的周围神经病变（CIPN）管理的新兴方法：C5a/C5aR轴的治疗潜力
Pain Ther. 2022 Dec;11(4):1113-1136. doi: 10.1007/s40122-022-00431-8. Epub 2022 Sep 13.